.
MergerLinks Header Logo

Announced

Cognos Therapeutics to go public via a SPA merger with Nocturne Acquisition in a $120m deal.

Financials

Edit Data
Transaction Value£99m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

Private

De-SPAC

Medical Equipment

Majority

Reverse Takeover

Merger

Domestic

Pending

United States

Single Bidder

medical devices

diagnostic equipment

Friendly

Synopsis

Edit

Cognos Therapeutics, a developer of diagnostic devices, agreed to go public via a SPA merger with Nocturne Acquisition in a $120m deal. "With over 15 years of research and development, Cognos has laid out a roadmap to deliver a novel targeted solution in the important field of brain cancer. Cognos' SINNAIS has the potential to become the world's first implantable device for local and metronomic delivery of therapeutics for treatment of neurological diseases. SINNAIS will enable unprecedented, targeted delivery of chemotherapeutics for persistent glioma and other solid tumors. It will provide physicians with an effective alternative method to monitor and treat tumor-based brain cancer and other neurological diseases," Henry Monzon, Nocturne Chairman and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US